Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nomura Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Nomura Holdings Inc trades at $9.66 (market cap $27.88B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.35% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NMR | |
|---|---|---|
Market Cap | $39.89B | $27.88B |
Sector | Health | Financials |
52-Week High | $491.22 | $9.66 |
52-Week Low | $278.09 | $6.30 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nomura Holdings (NMR) trades at $9.66, up 1.26% today, with a bullish technical signal from moving averages. The company reported record annual revenue of $1.66 trillion and net income of $340.74 billion for 2025, driving a net income margin of 20.49%. Recent news highlights strong wholesale revenue growth and strategic acquisitions, while analyst consensus shows a hold-heavy rating with 33% buy recommendations.
The outlook is mixed; robust profitability and expansion in core segments support upside, but consecutive earnings misses and rising debt-to-asset ratios pose risks. Investor sentiment is cautiously optimistic, with technical indicators suggesting near-term momentum but overbought conditions on shorter-term RSI readings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
